ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Hong Kong · Delayed Price · Currency is HKD

3.520

+0.090 (2.62%)

Jul 10, 2026, 11:53 AM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Biotechnology	154.29M	74.15M	7.70M	5.69M	13.81M
Biotechnology Growth	108.09%	863.60%	35.24%	-58.79%	-
Total	154.29M	74.15M	7.70M	5.69M	13.81M
Total Growth	108.09%	863.60%	35.24%	-58.79%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
United States of America	154.20M	74.01M	-	-
United States of America Growth	108.35%	-	-	-
PRC	97.00K	139.00K	386.00K	538.00K
PRC Growth	-30.22%	-63.99%	-28.25%	-
Total	154.29M	74.15M	386.00K	538.00K
Total Growth	108.09%	19109.59%	-28.25%	-